Avid Bioservices Inc (CDMO)

[cjgaddy]

2004 Interview with Steve Worsley, during his 5yr. stint with Raven Biotechnologies, ultimately acquired by MacroGenics…

11-2004: “The Monoclonal Antibody Business Landscape: An Interview with Stephen Worsley of Raven Biotechnologies”
CHI's Molecular Med Monthly Newsletter (CHI=Cambridge Healthech Inst.)
http://www.chidb.com/newsarticles/issue48_1.asp

= = = = = = = = = = = = = =
11-2013: Stephen Worsley joins Peregrine as VP of Bus.Dev. http://tinyurl.com/mmet4eb

= = = = =LinkedIN 12-12-13:
Stephen Worsley – VP, Business Development, Peregrine Pharmaceuticals (beg. 11-2013)
http://www.linkedin.com/pub/stephen-worsley/26/b35/271
Current:
• VP, Business Development, Peregrine Pharmaceuticals
• Board Advisor, OpenPlacement (a Rock Health graduate company)
PAST:
• CBO/VP Sales & Licensing, Centrose Pharmaceutical 2011-13
• VP, Business Dev., Intrexon Corp. 2010-11
• VP, Business Dev., Zosano Pharma (Johnson & Johnson spinout) 2008-10
• VP, Business Dev., Raven Biotechnologies (acquired by MacroGenics) 2003-08 (5 years)
• Dir. of Business Dev., Abgenix (acq. by AMGEN) 1999-2003
• Dir. of Business Dev., Tripos Drug Discovery 1996-99
• Dir. of Business Dev., OHM Technologies (acq. by Carlyle Group) 1990-96
• Marketing Manager, Symbion Cardiovascular Systems 1986-88
Education:
• Univ. of Utah - BS, Economics (chem-minor) 1986
• Univ. of Washington – MBA, Finance 1990
• Johns Hopkins Univ. - MS, Biotechnology (In process)

- - - - - - - - - - - - - - -
MGT. PROFILE ON PEREGRINE’S WEBSITE:
STEPHEN T. WORSLEY – VP, BUSINESS DEVELOPMENT
Stephen Worsley was appointed VP of Business Development in November 2013, bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Prior to joining Peregrine he was Chief Business Officer at Centrose Pharmaceuticals and prior to that he held the position of VP of Business Development at Intrexon, Zosano Pharma, (a spin out of Johnson & Johnson) and Raven Biotechnologies (acquired by MacroGenics). In addition, he was Director of Business Development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen holds an MBA in finance from the Univ. of Washington and a Bachelor of Science in international economics and finance from the Univ. of Utah.
http://www.peregrineinc.com/about-us/management-team.html